Expanded Access to 0.5 mg eRapa for Familial Adenomatous Polyposis (eRapa-FAP)
Expanded Access Program for 0.5 mg eRapa in Familial Adenomatous Polyposis
研究概览
详细说明
amilial adenomatous polyposis (FAP) is an inherited cancer predisposition syndrome characterized by the development of numerous colorectal adenomas and an increased risk of colorectal and other gastrointestinal malignancies. Although prophylactic surgery substantially reduces the risk of colorectal cancer, patients frequently continue to develop adenomas in the remaining gastrointestinal tract, and effective medical therapies to reduce polyp burden are limited.
Rapamycin inhibits the mammalian target of rapamycin (mTOR) signaling pathway, which regulates cell growth, proliferation, and survival. Dysregulation of mTOR signaling has been implicated in intestinal tumorigenesis associated with FAP, providing a biological rationale for mTOR inhibition as a therapeutic approach.
This expanded access program is intended to provide treatment with 0.5 mg eRapa (encapsulated rapamycin) for eligible patients with FAP when participation in a clinical trial is not feasible or available and no comparable or satisfactory therapeutic alternatives exist. Treatment decisions, dosing, duration of therapy, and clinical monitoring will be determined by the treating physician in accordance with the program inclusion and exclusion policy. Patients will undergo appropriate assessments to monitor safety, tolerability, and clinical status throughout treatment.
研究类型
扩展访问类型
- 个体患者
联系人和位置
参与标准
资格标准
适合学习的年龄
- 孩子
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
- Patient is post pubertal and reached full adult height
- Patient has FAP confirmed by APC genotype mutation tesing or a history of FAP in one of the parents. Genetic mosaics or Attenuated (as well as classical) FAP may participate
- Patient has significant colorectal and/or duodenal FAP disease burden.
Exclusion Criteria:
- Patient has existing carcinoma or high-grade dysplasia in the GI tract and/or requires imminent definitive surgical intervention (either partial or complete colectomy or duodenectomy).
- Patient with an acquired or congenital immunodeficiency, active and clinically significant tuberculosis, bacterial, fungal, or viral infections, including HIV.
- Patient has clinically significant elevations of hepatic enzymes or bilirubin, or other evidence of active hepatitis.
- Patient has clinically significant impairment of renal function.
- Patient has a history or evidence of clinically significant hyperlipoproteinemia or hypertriglyceridemia.
- Patient has active or recurrent bouts of pancreatitis, or clinically significant elevations of lipase or amylase.
- Patient is taking medications that are considered strong inducers or inhibitors of cytochrome P450 (CYP) 3A4/5 or strong inducers or inhibitors of P-glycoprotein 1 (P-gp1) that cannot be discontinued at least 1 week prior to first dose of treatment intervention and for the duration of the treatment.
- Patients with known hypersensitivity to rapamycin (sirolimus) or any of the excipients in eRapa.
- Sexually active patients who are unwilling to use a highly effective contraceptive method and to refrain from donating gametes (sperm or oocytes) throughout the time they are receiving eRAPA and for 12 weeks beyond that time, and to refrain from breast-feeding their children while on treatment.
- Patients who are pregnant or who are trying to become pregnant while taking eRapa.
- Patients unwilling or unable to undergo continued endoscopic surveillance in accordance with standards of care while taking eRapa.
- Patient has Mutations in the MUTYH gene.
学习计划
研究是如何设计的？
合作者和调查者
出版物和有用的链接
研究记录日期
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.